Pharma industry bullish on complex generics and biosimilars

While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side

Biocon Biologics and Viatris receive European Commission approval for Kixelle, Biosimilar Insulin Aspart

The centralized marketing authorization granted by the EC is valid in all EU Member

Biocon Biologics to offer its oncology biosimilars in 30+ countries

The partnership is a significant step in delivering advanced cancer therapies to patients.

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.

Industry leaders call for a new era of collaboration, innovation, and self-reliance

Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence

Jubilant Pharmova posts consolidated Q2 FY26 PAT at Rs. 120.3 Cr

Indegene posts consolidated Q2 FY26 PAT at Rs. 102.1 Cr

Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr

Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025

Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr

Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025